Selection of hormone-responsive advanced breast cancer with a cytoplasmic estrogen receptor assay. Analysis of 100 cases.
One hundred women with advanced breast cancer were treated with endocrine therapy alone and the clinical response was correlated with the estrogen receptor status of the tumor as determined by a fluorescent histochemical assay designed to estimate the percentage of cancer cells with high cytoplasmic estrogen binding activity. Using clinical response rates as the standards for measurement, this histochemical method showed an 84% sensitivity, a 74% specificity, a 76% positive predictive value and an 82% negative predictive value. These results indicate that the histochemical assay may serve as a supplementary means to identify hormone-responsive mammary carcinomas and as a research tool to study the biology of this group of tumors.
Chen
P Z
PZ
Department of Surgery, First Affiliated Hospital of West China University of Medical Sciences, Sichuan, People's Republic of China.
Mei
Z
Z
Yao
X Y
XY
Meng
X G
XG
D001943:Breast Neoplasms / Q000032:analysis* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D005453:Fluorescence; D006651:Histocytochemistry; D006801:Humans; D009367:Neoplasm Staging; D010052:Ovariectomy; D011446:Prospective Studies; D011960:Receptors, Estrogen / Q000032:analysis*; D013629:Tamoxifen / Q000627:therapeutic use
D011960:Receptors, Estrogen; D013629:Tamoxifen